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Abstract
Preoccupation about potential deleterious effects of pharmaceuticals in the environment is
growing fast. Psychiatric pharmaceuticals have received particular attention because of their
increasing use and their potential impacts on many living beings due to their effects on
phylogenetically highly conserved neuroendocrine systems. Recent studies that have shown
thatmany pharmaceuticals (including psychotropics) bioaccumulate through the web food have
raised this concern into new heights. As professionals working in the field of psychiatry and
academia, we believe we are about to enter a new era with regard to pharmacotherapy. We
estimate drug pollution will have a major impact on our daily practice in a way we are just
starting to imagine. So far, this problem has largely been ignored by healthcare professionals,
who are the ones prescribing and dispensing pharmaceuticals. We are convinced that increasing
awareness among these professionals will be a key element to effectively fight against drug
pollution.
Concern about potential deleterious effects of pharmaceuticals in the environment is rapidly
growing worldwide [1]. Drug pollution has been considered as a “wicked problem” by the Dutch
authorities: it is a complicated and diffuse problem that is characterized by scientific uncer-
tainties, a large number of interested parties with different values and interests, and institutional
complexity [2]. Once excreted by patient’s urine or feces, drugs, in the best of scenarios, are
transported to sewage treatment plants, where actual widespread technology does not guarantee
they are efficiently eliminated. Psychiatric pharmaceuticals have received particular attention
because of their increasing use and their potential impacts on many living beings due to their
effects on phylogenetically highly conserved neuroendocrine systems. Recent studies, however,
have raised this preoccupation into new heights. Richmond et al. showed that many pharma-
ceuticals (including psychotropics) bioaccumulate through the food web, estimating that platy-
puses in Australia receive as much as half of the human antidepressant dose daily [3].
Nowadays, despite concerns may arise in the environmental risk assessment (ERA) of the
drug presented to the European Medicines Agency (e.g., asenapine is believed to “have potential
endocrine disruption properties [4]” and vortioxetine “is expected to pose a risk for the
environment [5]”), environmental aspects are not considered in the global risk–benefit assess-
ment of drugs for human use. Besides, these ERAs only became mandatory in 2005, so abundant
knowledge gaps about many drugs which are extensively used in routine clinical practice still
exist.
As professionals working in the field of psychiatry and academia, we believe we are about to
enter a new era with regard to pharmacotherapy. We estimate drug pollution will have a major
impact on our daily practice in a way we are just starting to imagine. Eco-sustainable or green
prescribing has already been proposed by some authors, although not pertaining to healthcare
[6]. For example, oxacepam, a drug that would be considered a wise choice for elderly people
because the benign pharmacokinetic profile (it is eliminated via glucuronidation), persists
without biodegradation in the bottom of lakes for decades [7]. Another relevant consequence
may affect patients, in the way they may feel guilty about taking certain drugs. For instance, a
depressed patient could become even more depressed when he hears about potential conse-
quences of the drug he is excreting with his urine. Taking environmentally unfavorable
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medication could further add to the stigma of a mental illness.
Additionally, psychiatric drugs are not popular even among people
who could benefit from them; therefore, the awareness that a drug
can have a deleterious impact on the environment can increase
some patient’s reluctance toward psychopharmacological reme-
dies. On the other hand, ecotoxicological aspects of psychiatric
pharmaceuticals could transform into a potent argument for the
antipsychiatry movement [8] and hospitals, could be banned or
restricted near ecosystem reserves, or may even become a “not-in-
my-backyard” institution.
The unwanted effects of drugs on ecosystems are gaining
momentum, at a speed, that soon, pressure to include environmen-
tal risk aspects on the benefit/risk ratio of new drug approvals
(already mandatory for veterinary products) will increase. In addi-
tion, ecotoxicological concernsmay affect not only the drug but also
the whole medicine itself. Think about inhaled loxapine, a recent
marketed antipsychotic for the treatment of agitation, which neces-
sitates that one lithium battery is discarded after each inhalation.
Besides, in the case of Abilify Mycite, an electronic circuit is
excreted with each ingested capsule.
As it occurs with ordinary pharmacovigilance, approved
drugs could be withdrawn from the market because of eco-
pharmacovigilance issues. Restricting the number of patients to
be treated with certain drugs could become a reality. Moreover, less
biodegradable drugs could become more expensive, and the phar-
maceutical industry could be forced to develop “green by design”
drugs, which are more biodegradable. Of course, a favorable envi-
ronmental profile can become an issue in drug promotion, as a
“favorable metabolic (or QTc, extrapyramidal) profile” has previ-
ously been raised to highlight a drug’s excellence.
So far, this problem has been addressed and discussed by
chemists, environmentalists, and biologists, but has largely been
ignored by healthcare professionals, who are the ones prescribing
and dispensing pharmaceuticals. In fact, as far as we are concerned,
issues about drug pollution are nowadays generally ignored in
Pharmacy and Medicine faculties. In line with the recommenda-
tions given by the Strategic Approach of the European Commis-
sion, we are convinced that increasing awareness among these
professionals will be a key element to effectively fight against drug
pollution. We believe neglecting drug pollution aspects could con-
tribute to the discredit of medicine, healthcare, and science in
general. It is time to realize we have a platypus in the room.
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